Gyre Therapeutics (GYRE) Notes Payables (2015 - 2017)

Gyre Therapeutics (GYRE) has reported Notes Payables for 3 consecutive years, with $5.1 million the latest figure, recorded in Q4 2017.

• In Q4 2017, Notes Payables fell 73.79% year-over-year to $5.1 million; the TTM figure through Dec 2017 stood at $5.1 million (down 73.79% YoY), while the FY2017 annual figure was $5.1 million, down 73.79% from the prior year.
• Notes Payables eased to $5.1 million in Q4 2017 per GYRE's latest filing, from $5.5 million in the prior quarter.
• Across five years, Notes Payables topped out at $34.8 million in Q3 2015 and bottomed at $130000.0 in Q2 2016.
• Historically, Notes Payables has averaged $14.7 million across 3 years, with a median of $9.2 million in 2017.
• On a YoY basis, Notes Payables climbed as much as 6354.59% in 2017 and fell as far as 81.5% in 2017.
• Gyre Therapeutics' Notes Payables stood at $33.7 million in 2015, then slumped by 42.5% to $19.4 million in 2016, then sank by 73.79% to $5.1 million in 2017.
• Business Quant data shows GYRE's Notes Payables at $5.1 million in Q4 2017, $5.5 million in Q3 2017, and $5.8 million in Q2 2017.